Published in Clin Vaccine Immunol on September 19, 2012
Repeated outbreaks of viral hemorrhagic fevers in Uganda. Afr Health Sci (2012) 1.14
A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis. Clin Orthop Relat Res (2015) 0.85
Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Med Microbiol Immunol (2015) 0.79
Immune memory to Sudan virus: comparison between two separate disease outbreaks. Viruses (2015) 0.79
Determination of specific antibody responses to the six species of ebola and marburg viruses by multiplexed protein microarrays. Clin Vaccine Immunol (2014) 0.78
Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors. Viruses (2016) 0.75
Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J Exp Med (2017) 0.75
Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI. Sci Rep (2017) 0.75
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Human asymptomatic Ebola infection and strong inflammatory response. Lancet (2000) 5.20
Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 4.96
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
An outbreak of Ebola in Uganda. Trop Med Int Health (2002) 4.66
Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol (1999) 4.32
Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis (1999) 4.18
ELISA for the detection of antibodies to Ebola viruses. J Infect Dis (1999) 3.92
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A (2012) 3.35
Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch Virol Suppl (2008) 3.22
Containing a haemorrhagic fever epidemic: the Ebola experience in Uganda (October 2000-January 2001). Int J Infect Dis (2004) 3.15
Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol (2004) 3.04
Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med (2012) 2.98
Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol (1992) 2.69
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24
Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol (2001) 1.93
A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol (2011) 1.84
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis (2010) 1.75
Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol (2011) 1.73
Functional mapping of the nucleoprotein of Ebola virus. J Virol (2006) 1.69
Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol (2001) 1.68
High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One (2010) 1.68
Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol (2001) 1.65
Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J Virol Methods (2005) 1.58
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol (2007) 1.52
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
Filoviruses: Interactions with the host cell. Cell Mol Life Sci (2008) 1.48
Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 1.29
Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol (2009) 1.28
Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis (2000) 1.25
Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med (2007) 1.23
Ebola virus: the search for vaccines and treatments. Cell Mol Life Sci (2001) 1.18
Structural basis for differential neutralization of ebolaviruses. Viruses (2012) 1.15
Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda. Virus Res (2005) 1.12
Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections. J Gen Virol (1998) 1.01
Seasonal variation in antibodies against Ebola virus in Kenyan fever patients. Lancet (1986) 0.83
Optical fiber immunosensor for the detection of IgG antibody to Rift Valley fever virus in humans. J Virol Methods (2007) 0.81
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity (2012) 2.35
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis (2011) 2.30
Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis (2007) 2.22
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells. PLoS Biol (2011) 2.02
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol (2011) 1.84
Influenza surveillance in 15 countries in Africa, 2006-2010. J Infect Dis (2012) 1.76
Inhibition of filovirus replication by the zinc finger antiviral protein. J Virol (2006) 1.76
The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure (2003) 1.75
Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J (2004) 1.73
Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J Virol (2002) 1.71
VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment. J Virol (2002) 1.63
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol (2006) 1.61
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). Virus Res (2004) 1.54
Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem (2005) 1.53
Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol (2013) 1.52
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47
Multivesicular bodies as a platform for formation of the Marburg virus envelope. J Virol (2004) 1.47
Phosphorylation of VP30 impairs ebola virus transcription. J Biol Chem (2002) 1.47
VP24 of Marburg virus influences formation of infectious particles. J Virol (2005) 1.46
The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway. J Virol (2004) 1.43
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest (2017) 1.39
Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci U S A (2012) 1.38
Convalescent Plasma and the Dose of Ebola Virus Antibodies. N Engl J Med (2017) 1.38
Morphology of Marburg virus NP-RNA. Virology (2002) 1.38
Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc Natl Acad Sci U S A (2007) 1.37
LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology (2005) 1.37
Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol (2005) 1.35
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol (2013) 1.34
Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis (2007) 1.33
First international quality assurance study on the rapid detection of viral agents of bioterrorism. J Clin Microbiol (2004) 1.33
Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis (2011) 1.33
Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J Virol (2005) 1.30
Current ebola vaccines. Expert Opin Biol Ther (2012) 1.30
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol (2010) 1.29
Ebola virus transcription activator VP30 is a zinc-binding protein. J Virol (2003) 1.29
Inclusion bodies are a site of ebolavirus replication. J Virol (2012) 1.29
Role of Ebola virus VP30 in transcription reinitiation. J Virol (2008) 1.28
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
VP40 octamers are essential for Ebola virus replication. J Virol (2005) 1.28
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res (2011) 1.24
Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem (2003) 1.24
Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology (2005) 1.24
Budding of Marburgvirus is associated with filopodia. Cell Microbiol (2006) 1.22
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci U S A (2011) 1.21
Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol (2011) 1.21
Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool. Emerg Infect Dis (2016) 1.20
Efficient budding of the tacaribe virus matrix protein z requires the nucleoprotein. J Virol (2010) 1.20
Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol (2006) 1.17
Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia (2007) 1.16
Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Protein Sci (2014) 1.16
Tacaribe virus but not junin virus infection induces cytokine release from primary human monocytes and macrophages. PLoS Negl Trop Dis (2011) 1.16
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog (2012) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Structural basis for differential neutralization of ebolaviruses. Viruses (2012) 1.15
An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12
Tsg101 is recruited by a late domain of the nucleocapsid protein to support budding of Marburg virus-like particles. J Virol (2010) 1.12
Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis (2013) 1.12
Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res (2004) 1.12
Establishment and application of an infectious virus-like particle system for Marburg virus. J Gen Virol (2010) 1.11
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol (2013) 1.11
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak. Emerg Infect Dis (2016) 1.08
Phosphorylation of Ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication. J Biol Chem (2013) 1.07
Role of the transmembrane domain of marburg virus surface protein GP in assembly of the viral envelope. J Virol (2007) 1.06
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res (2013) 1.04
Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection. PLoS Negl Trop Dis (2010) 1.04